These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32735903)

  • 21. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    ; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
    JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline Factors Affecting Changes in Diabetic Retinopathy Severity Scale Score After Intravitreal Aflibercept or Laser for Diabetic Macular Edema: Post Hoc Analyses from VISTA and VIVID.
    Dhoot DS; Baker K; Saroj N; Vitti R; Berliner AJ; Metzig C; Thompson D; Singh RP
    Ophthalmology; 2018 Jan; 125(1):51-56. PubMed ID: 28764888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
    Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
    Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.
    Egan C; Zhu H; Lee A; Sim D; Mitry D; Bailey C; Johnston R; Chakravarthy U; Denniston A; Tufail A; Khan R; Mahmood S; Menon G; Akerele T; Downey L; McKibbin M; Varma A; Lobo A; Wilkinson E; Fitt A; Brand C; Tsaloumas M; Mandal K; Kumar V; Natha S; Crabb D;
    Br J Ophthalmol; 2017 Jan; 101(1):75-80. PubMed ID: 27965262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
    Maguire MG; Liu D; Glassman AR; Jampol LM; Johnson CA; Baker CW; Bressler NM; Gardner TW; Pieramici D; Stockdale CR; Sun JK;
    JAMA Ophthalmol; 2020 Mar; 138(3):285-293. PubMed ID: 31999300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
    Roberts PK; Vogl WD; Gerendas BS; Glassman AR; Bogunovic H; Jampol LM; Schmidt-Erfurth UM
    JAMA Ophthalmol; 2020 Sep; 138(9):945-953. PubMed ID: 32722799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.
    ; ; Aiello LP; Beck RW; Bressler NM; Browning DJ; Chalam KV; Davis M; Ferris FL; Glassman AR; Maturi RK; Stockdale CR; Topping TM
    Ophthalmology; 2011 Dec; 118(12):e5-14. PubMed ID: 22136692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
    Kalra G; Wykoff C; Martin A; Srivastava SK; Reese J; Ehlers JP
    Ophthalmol Retina; 2024 Feb; 8(2):116-125. PubMed ID: 37696393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.
    Sepah YJ; Sadiq MA; Boyer D; Callanan D; Gallemore R; Bennett M; Marcus D; Halperin L; Hassan M; Campochiaro PA; Nguyen QD; Do DV;
    Ophthalmology; 2016 Dec; 123(12):2581-2587. PubMed ID: 27707550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.